The improved anti-tumor immunity in immunogenic tumors could be ascribed towards the inhibition of PTP1B/PTPN2 in T cells, While in cold tumors, Compound-182 elicited direct effects on both of those tumor cells and T cells. Importantly, treatment with Compound-182 rendered normally resistant tumors delicate to ?-PD-one therapy. Our results set up t